Drug Profile
Telanmir
Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Institute of Biomedical Research Alberto Sols
- Developer Advanced Medical Projects
- Class Peptides
- Mechanism of Action Telomerase activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ataxia telangiectasia
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Ataxia telangiectasia in Spain (IV)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Ataxia-telangiectasia in Spain (IV)
- 15 Dec 2016 Preclinical trials in Ataxia telangiectasia in Spain (IV)